Regeneron (REGN) Tops Q1 EPS by 35c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Regeneron Reports First Quarter 2018 Financial and Operating Results
May 3, 2018 6:30 AM EDTTARRYTOWN, N.Y., May 3, 2018 /PRNewswire/ -- Â
First quarter 2018 GAAP net income per diluted share increased by 93% to $4.16 versus first quarter 2017 and first quarter 2018 non-GAAP net income per diluted share increased 60% to $4.67 versus first quarter 2017 First quarter 2018 EYLEA® (aflibercept) Injection U.S. net sales increased 15% to $984 million versus first quarter 2017 and first quarter 2018 EYLEA global net sales(1) increased 20% to $1.61 billion versus first quarter 2017 Positive results reported from Praluent® (alirocumab) ODYSSEY OUTCOMES study Agreement reached with Express Scripts that provides patients with straightforward and more... More